Fig. 3From: Safety, pharmacokinetics and efficacy of SCT200, an anti-EGFR monoclonal antibody in patients with wild-type KRAS/NRAS/BRAF metastatic colorectal cancer: a phase I dose-escalation and dose-expansion studyProgression-free survival (PFS) (a) and overall survival (OS) (b) in the 6.0 mg/kg QW dose-expansion group. CI Confidence interval, QW Quaque weekBack to article page